Pharmaceutical company Revolo has announced that it has finished enrolling participants in its Phase 2 proof-of-concept, randomised, double-blind, placebo-controlled clinical trial investigating the immune-resetting molecule, '1104, for the treatment of patients with eosinophilic oesophagitis (EoE).

The enrolment has completed ahead of schedule and the company is anticipating topline data by the end of the year.

Molecule '1104's ability to reset the immune system from a pro-inflammatory state to a regulated homeostatic state has led researchers to believe it can potentially eliminate the debilitating symptoms of EoE.

Principal investigator and EOS Network Medical Advisor, Evan Dellon MD, said:

Patients with EoE are very much in need of effective and safe therapies that treat this life-changing disease. This study will inform us about how ‘1104 affects histology and the associated inflammatory biomarkers, key components of the complex physiopathology of the disease.

Links

• Revolo Biotherapeutics press release
• ClinicalTrials.gov trial listing